当前位置: 首页 > 期刊 > 《中国实用医药》 > 2009年第2期
编号:11727501
利妥昔单抗在B细胞非霍奇金淋巴瘤中的应用进展(4)
http://www.100md.com 2009年1月15日 《中国实用医药》 2009年第2期
     [18] Milpied N,Deconinck E,Gaillard F,et al.Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stemcell support.New Engl J Med,2004,350(13):1287-1295.

    [19] Naparstek E.The role of the anti-CD20antibody rituximab in hematopoietic stem cell transplantation for non-Hodgkin lymphoma.Curr Hematol Rep,2005,4(4):276-283.

    [20] Hoerr Al ,Gao F,Hidalgo J,et al.Effects of pretransplantation treatment with rituximab on outcomes of autologous stem cell transplantation for non-Hodgkin’s lymphoma.J Clin Onco1,2004,22(22):4561-4566.

    [21] Pfreundschuch M,Kloess M,Schmits R,et al.Six,not eight cycles of Bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL):results of the RICOVER-60 trial of the German High-grade Non-Hodgkin Lymphoma Study Group (DSHNHL)[abstract].Blood,2005,106:9a.

    [22] Ghielmini M,Schmitz S-FH,Cogliatti SB,et al.Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.Blood,2004,103(12):4416-4423., http://www.100md.com(刘丽萍 冉学红 任翠爱)
上一页1 2 3 4